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Abstract: The molecular similarity of multidrug resistance (MDR) inhibitors was evaluated 
using the point centred atom charge approach in an attempt to find some common features 
of structurally unrelated inhibitors. A series of inhibitors of bacterial MDR were studied and 
there is a high similarity between these in terms of their shape, presence and orientation of 
aromatic ring moieties. A comparison of the lipophilic properties of these molecules has 
also been conducted suggesting that this factor is important in MDR inhibition. 
Keywords: MDR, multidrug resistance, inhibitor, molecular similarity, SAR, ab initio. 
 
Introduction 
MDR or multidrug resistance is responsible for many forms of resistance in bacteria, fungi and 
human tumours [1]. This resistance functions by the presence of membrane bound efflux pumps, 
which actively export therapeutics from the cell resulting in a low intracellular ineffective 
concentration of the drug [2]. These pumps recognize a wide variety of structurally unrelated 
compounds [3] and it is believed that MDR inhibitors bind directly to the hydrophobic region of the 
efflux pump thus preventing the drug transport [4].  
There has been much research conducted to find inhibitors of these proteins, particular in human 
tumour resistance as reviewed by Stouch and Gudmundsson [5].  Some  progress  has been reported on  
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the structure-activity relationships (SARs) for inhibitors of bacterial efflux pumps [6], but further work 
is necessary to fully explain the mechanism of MDR efflux inhibition, since most potent inhibitors of 
the NorA MDR pump of Staphylococcus aureus come from totally different chemical classes. This is 
unusual since it seems that there is no common pharmacophore that causes inhibition of MDR.  
We have modelled and explored biomolecular similarities of a series of representative MDR 
inhibitors of the NorA pump from different classes (Scheme 1) on the basis of molecular interaction 
potentials and report here some structural features required for MDR inhibition.  
 
Computational Methods 
The inhibitors studied were optimized by Gamess-US ab initio software package [7] and HF/6-
311G(*) basis set (except for the INF 277 where we have used HF/6-31G(*) basis set). The molecular 
similarity was evaluated by MIPSIM software [8] using COMP module and a classical atom-centred 
point-charge distribution (PTC_MEP) approach. The reserpine and GG918 molecules were too big for 
the MIPSIM calculations, and were spilt into 3 units for comparison with other inhibitors (denoted as 
A, B and C in Scheme 1). The theoretical values of logP, surface area and volume were calculated by 
SciLogP 3.0 [9], Vega [10] and Chem3D [11] software packages. Visualization of the results was 
achieved by ViewerLite [12] and ICM Lite [13] software packages. 
 
Results and Discussion 
The efflux pump NorA plays an important role in resistance to fluoroquinolone antibiotics of the 
major human pathogen Staphylococcus aureus, which is highly problematic in the clinical environment 
[14]. The restoration of antibiotic efficacy could be achieved by using inhibitors, molecules that 
potentiate the activity of standard antibiotics against MDR cells. Efflux inhibitors are from a wide 
range of structural classes and representative molecules for different classes were studied here. The 
experimental results of MDR modulation for chosen inhibitors are shown in Table 1. These results are 
taken from the literature [15] or from one of the authors [16, 17]. Compounds with no potential for 
MDR inhibition are shown in Scheme 2. It is believed that inhibitors of these transport processes act 
by directly binding to hydrophobic regions of MDR proteins causing inhibition of antibiotic removal 
[4]. Since a wide range of MDR inhibitors have been discovered and with no apparent pharmacophore 
detected, we have assumed that interactions important for MDR inhibition must be non-specific. The 
molecular electrostatic potential could be very important for the formation of a potential hydrogen 
bond network and other interactions between MDR inhibitor and efflux pump, and it could also play a 
significant role in molecular recognition.  
In the absence of an explanation for the MDR inhibition mechanism, we have decided to evaluate 
the importance of molecular electrostatic potential in these processes. The ab initio optimised 
geometries of selected inhibitors of  the  NorA  efflux pump were  compared using atom-centred point- 
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Table 1. MDR modulation results for NorA inhibitors (5’-MHC depicted 5’-methoxyhydnocarpin). 
Inhibitor Drug Inhibition Reference 
INF 240 Ciprofloxacin 0.12* Markham et al., 1999. [15] 
INF 271 Ciprofloxacin 0.12* Markham et al., 1999. [15] 
INF 277 Ciprofloxacin 0.15* Markham et al., 1999. [15] 
INF 392 Ciprofloxacin 0.28* Markham et al., 1999. [15] 
INF 55 Ciprofloxacin 0.25* Markham et al., 1999. [15] 
5’-MHC Norfloxacin 4** Stermitz et al., 2000. [18] 
Reserpine Norfloxacin 4** Gibbons et al., 2003. [16] 
GG918 Norfloxacin 8** Gibbons et al., 2003a. [16] 
Diterpene from  
Lycopus europaeus  
Norfloxacin ND Gibbons et al., 2003b. [16] 
Epigallocatechin- 
3-O-gallate  
Norfloxacin ND Gibbons, unpublished data [2003] 
*FIC index - <0.5 is considered to be indicator of synergistic activity. 
**Fold reduction in minimum inhibitory concentration (MIC) of antibiotic in the presence of inhibitor. 
ND - no drug potentiation. 
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charge distribution and results are presented in Table 2 in the form of a similarity matrix. Reserpine 
and GG918 had to be split into three portions, and those are defined in the Scheme 1. 
The similarity index for all pairs of inhibitors was between 0.644 and 0.932, depending on the size 
of the compared molecules. The results for the parts of reserpine and GG918 are to be taken with 
caution due to the relatively small sizes of examined moieties. Direct correlation between similarity 
and fold of modulation cannot be fully examined due to differences in the representation of 
experimental data, however, the following could be emphasised: 
a) INF 271 and INF 277 have a similar potency of MDR inhibition and similarity index is also 
high –  0.817; 
b) 5'-methoxyhydnocarpin (5’-MHC) and INF 240 are potent MDR inhibitors and have a high 
similarity index. 
Due to the difference in the size of molecules, a more detailed analysis was carried out by visually 
comparing inhibitors. 
 
 
 
Table 2. Final similarity matrix for MDR inhibitors of the NorA pump calculated by MIPSIM using 
point charges. Three parts of reserpine were denoted as Reserpine A, Reserpine B and Reserpine C, 
and three parts of GG918 were denoted as GG918 A, GG918 B, and GG918 C. Similarity between 
parts that belong to the same molecule were not considered. 
 5’-MHC INF 240 INF 271 INF 277 INF 392 INF 55 
5’-MHC 1.000      
INF 240 0.840 1.000     
INF 271 0.735 0.733 1.000    
INF 277 0.704 0.673 0.817 1.000   
INF 392 0.740 0.751 0.781 0.722 1.000  
INF 55 0.729 0.707 0.866 0.803 0.725 1.000 
Reserpine A 0.690 0.735 0.870 0.754 0.719 0.932 
Reserpine B 0.691 0.616 0.817 0.813 0.739 0.808 
Reserpine C 0.699 0.649 0.717 0.695 0.677 0.737 
GG918 A 0.669 0.713 0.818 0.755 0.707 0.915 
GG918 B 0.644 0.703 0.759 0.699 0.670 0.839 
GG918 C 0.716 0.692 0.795 0.722 0.646 0.824 
Diterpene from Lycopus 
europaeus  
0.681 0.566 0.763 0.807 0.722 0.720 
Epigallocatechin-3-O-gallate 0.682 0.670 0.825 0.868 0.733 0.750 
 
 
Int. J. Mol. Sci. 2004, 5   
 
42
From the figures of the best fit between pairs of inhibitors, some observations are apparent: 
a) 5'-methoxyhydnocarpin and INF 240 have the same shape and some polar groups in a similar 
position (Figure 1). Note the absence of nitrogen atom in 5’-MHC; 
b) INF 271 and INF 277 have a similar shape and both have a nitrogen atom in the middle of the 
molecule (Figure 2); 
c) INF 55 is planar and different in shape compared to INF 271, however both molecules have a 
nitrogen atom in the middle of molecule and aromatic rings from both molecules are almost 
parallel to each other (Figure 3); 
d) there is high similarity between INF 271 and parts of Reserpine and GG918 (Figure 4 and 
Figure 5, respectively), again with a nitrogen atom in the middle of the molecule; 
e) all potent MDR inhibitors have aromatic rings in the areas that contain high similarity. 
In Figures 6 and 7, similarities between epigallocatechin-3-O-gallate (EGG) and two Influx 
compounds are depicted. However, EGG is not a potentiator of drugs in bacterial  MDR processes, and 
possibly is therefore not an inhibitor of bacterial MDR efflux. This can possibly be explained by 
visually examining the best fit between EGG and the two Influx compounds (INF271 and INF277). 
The similarity index is very high for both of these combinations but it can be observed that there is a 
poor fit between EGG and the aromatic moieties of both of these compounds. Looking at the fit 
between INF277 and the diterpene from Lycopus europaeus, there is a high calculated similarity but 
again this diterpene is not a potentiator of MDR drugs and this is probably due to the poor fit that this 
has with aromatic moieties of other MDR inhibitors e.g. INF277 (Figure 8). 
 
 
 
Figure 1. Best fit of optimized 5'-methoxyhydnocarpin (sticks) and INF 240 (wireframe) structures. 
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Figure 2. Best fit of optimised INF 271 (sticks) and INF 277 (wireframe) structures. 
 
 
 
 
 
 
 
 
Figure 3. Best fit of optimised INF 271 (sticks) and INF 55 (wireframe) structures. 
Int. J. Mol. Sci. 2004, 5   
 
44
 
 
 
 
 
Figure 4. Best fit of optimised INF 271 (sticks) and Reserpine A (wireframe) structures. 
 
 
 
 
 
 
 
 
Figure 5. Best fit of optimised INF 271 (sticks) and GG918 A (wireframe) structures. 
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Figure 6. Best fit of optimised INF277 (sticks) and Epigallocatechin-3-O-gallate (wireframe) 
structures. 
 
 
 
 
 
 
 
Figure 7. Best fit of optimised INF271 (sticks) and Epigallocatechin-3-O-gallate (wireframe) 
structures. 
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Figure 8. Best fit of optimised INF277 (sticks) and diterpene from Lycopus europaeus 
(wireframe) structures. 
 
 
We have also studied some theoretical parameters i.e. clogP and logP, (Table 3), however there is 
no obvious correlation with MDR modulation results. However clogP is generally lower for non-MDR 
inhibitors, the exception to this is INF55, which is a small molecule and one of the poorest MDR 
inhibitor of the INF series. 
 
Table 3. Theoretically calculated values of clogP, logP, surface area and volume of all studied MDR 
inhibitors and non potentiators by different methods. 
Inhibitor clogP 
(Chem3D) 
logP  
(Chem3D)
logP 
(SciLogP)
logP 
(Vega)
lipole
(Vega) 
Surface area 
(A2) 
Volume 
(A3) 
5’-MHC 3.47 2.33 6.23 5.43 2.92 482.9 410.5 
INF 240 5.14 4.73 6.04 3.03 1.43 396.5 328.5 
INF 271 4.28 3.38 5.67 3.76 2.77 316.9 263.9 
INF 277 6.02 5.12 6.02 6.73 2.29 408.0 361.2 
INF 392 4.25 5.60 6.15 4.48 1.29 419.8 354.0 
INF 55 0.93 3.68 5.09 4.92 5.12 248.7 207.2 
Reserpine 3.85 2.69 6.08 4.38 1.10 656.0 546.6 
GG918 4.21 5.03 6.12 5.60 0.89 629.9 536.0 
Diterpene from  
Lycopus europaeus  
2.45 3.65 6.23 3.34 0.73 497.84 425.59
Epigallocatechin- 
3-O-gallate 
1.49 2.07 6.21 6.62 2.61 429.3 363.6 
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Conclusions 
This study has shown that there is a high similarity between inhibitors of the NorA MDR 
transporter with similarity index higher than 0.6. However, there is no obvious correlation between 
similarity index and potential as MDR inhibitor, since some non-potentiators have high similarity 
index with MDR inhibitors. The important feature that differentiates inhibitors and non-inhibitors is 
the shape of the molecule and relative position of the aromatic moieties present in the molecule.  
Although in most inhibitors there is a nitrogen atom in the middle of the molecule, it is not 
essential, for example 5’-MHC has no such feature. This confirms the assumption that the interactions 
occurring during MDR inhibition must be non-specific. The shape of the molecule, aromatic rings and 
presence of some polar atoms will determine the potency of MDR inhibition. This study should be 
expanded to encompass a further series of inhibitor and non-inhibitor molecules of MDR processes of 
NorA in order to derive rules for the in silico screening for MDR inhibitors. 
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